ASPIRIN’S PRINCIPLE
BENEFITS: 1) FIRST MYOCRADIAL INFRACTION 32% 2)
CUTS COLON-CANCER DEATH RATE BY 50% 3) BREAST
CANCER 20% 4) CESAREAN SECTION 400% 5) LUNG CANCER 33% 6) PANCREATIC CANCER 53% 7) ALSHEIMER'S DISEASE 42% 8) DIABETES CAUSED BLINDNESS, CORONARY ARTERY DISEASE, STROKE, AND KIDNEY FALURE REDUCED. Laboratory studies have suggested that by inhibiting the COX-1 and COX-2 enzymes, aspirin may enhanced
programmed cell death (apoptosis) and inhibit the development of blood vessels (angiogensis) that feed a tumor |
|
Carefully controlled study show that all class of non-aspirin NSAIDs cause increased risk of myocardial
infraction. ARCHIVES OF INTERNAL MEDICINE, Vol. 165 No. 9. Risk of Hospitalization for Myocardial Infarction Among Users of Rofecoxib,
Celecoxib, and Other NSAIDs A Population-Based
Case-Control Study Søren P. Johnsen, MD, PhD; Heidi Larsson, MSc; Robert E. Tarone, PhD; Joseph K.
McLaughlin, PhD; Bente Nørgård, MD, PhD; Søren Friis, MD; Henrik T. Sørensen, DMSc Arch Intern Med. 2005;165:978-984. Background It remains uncertain if the excess cardiovascular risk of rofecoxib and celecoxib reported
in clinical trials is present in routine practice and whether the use of other nonaspirin nonsteroidal
anti-inflammatory drugs (NSAIDs) also carries an increased cardiovascular risk. We performed a population-based
case-control study to examine the risk of myocardial infarction (MI) among users of various categories of
nonaspirin NSAIDs. Methods Using data from hospital discharge registries in the counties of North Jutland, Viborg,
and Aarhus, Denmark, and the Danish Civil Registration System, we identified 10 280 cases of first-time
hospitalization for MI and 102 797 sex- and age-matched non-MI population controls. All prescriptions
for nonaspirin NSAIDs filled before the date of admission for MI were identified using population-based prescription
databases. Relative risk estimates for MI were adjusted for a history of cardiovascular disease, hypertension,
diabetes mellitus, chronic bronchitis or emphysema, alcoholism, liver cirrhosis, upper gastrointestinal
bleeding, rheumatoid arthritis, systemic lupus erythematosus and the use of high-dose aspirin, platelet inhibitors,
insulin or oral hypoglycemic drugs, antihypertensive drugs, lipid-lowering drugs, oral anticoagulants, nitrates,
penicillamine, gold, oral glucocorticocoids, and hormone therapy before the date of admission for MI.
Results Current users of rofecoxib had an elevated risk estimate for hospitalization for MI compared
with nonusers of any category of nonaspirin NSAIDs (adjusted relative risk [ARR], 1.80; 95% confidence
interval [CI], 1.47-2.21). Increased risk estimates were also found among current users of celecoxib (ARR,
1.25; 95% CI, 0.97-1.62), other cyclooxygenase-2 selective inhibitors (ARR, 1.45; 95% CI, 1.09-1.93), naproxen
(ARR, 1.50; 95% CI, 0.99-2.29), and other conventional non-aspirin NSAIDs (ARR, 1.68; 95% CI, 1.52-1.85). The highest
ARRs were found among new users of all examined drug categories. Conclusions Current and new users of all classes of non-aspirin NSAIDs had elevated relative risk
estimates for MI. Although the increased risk estimates may partly reflect unmeasured bias, they indicate
the need for further examination of the cardiovascular safety of all non-aspirin NSAIDs. From Harvard Health Publications at www.health.harvard.edu, Harvard journal draws same conclusions
as above article. Ibuprofen, aspirin, and COX-2s all belong to the class of medicines called nonsteroidal
anti-inflammatory drugs (NSAIDs). Most of them boost blood pressure and can counteract the effect of some blood-pressure drugs.
They can also impair blood vessels’ ability to relax and may stimulate the growth of smooth muscle cells inside arteries. All these changes can contribute to the artery-clogging process known as atherosclerosis. Researchers have determined that use of a COX-2 inhibitor increases the chances of having
a heart attack. Vioxx, which was taken off the market because of possible heart complications, may lead to or worsen heart
failure — but so can traditional NSAIDs. In general, cardiovascular side effects are most likely to happen in people
with existing heart disease or those at high risk for it. It is very easy to take the safety of medications for granted, and sometimes we get a
harsh reminder that even FDA-approved medications carry risks as well as benefits. Take, for example, the story of the pain
relievers Vioxx and Bextra. These COX-2 specific nonsteroidal anti-inflammatory drugs (NSAIDs) were withdrawn from the market
after being linked with cardiovascular problems. Now it turns out that even some of our old standby NSAIDs aspirin and ibuprofen
carry some cardiovascular risks you should be aware of. This issue of HEALTHbeat explains these new concerns and who may be
at particular risk.—Nancy Ferrair, Managing Editor of Harvard Health Publications.
Unfortunate most doctors still are unaware that all NSAIDs promote the development of
atherosclerosis—the one exception being ASPIRIN. The problem lies with the 800 pound guerrilla (big PHARMA) dominating
the dissemination of medical information. The new letter failed to address the
fact that the only health risk associated from aspirin or stomach bleeds and those associated with reduced ability to form
blood clots. However this reduced ability also lowers the risk of myocardial
infractions.--jk.
INTERNAL SITE SEARCH ENGINE by Google
Disclaimer:
The information, facts, and opinions
provided here is not a substitute for professional advice. It only indicates
what JK believes, does, or
would do. Always consult your primary
care physician for any medical advice, diagnosis, and treatment. |